CD79A Human
Sf9, Insect cells.
CD79a Molecule, Membrane-Bound Immunoglobulin-Associated Protein, CD79A Antigen (Immunoglobulin-Associated Alpha), CD79a Molecule, Immunoglobulin-Associated Alpha, Surface IgM-Associated Protein, MB-1 Membrane Glycoprotein, Ig-Alpha, IGA, B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain, CD79a Antigen, MB-1, MB1.
Greater than 95.0% as determined by SDS-PAGE.
Description
CD79A Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 119 amino acids (33-143a.a.) and having a molecular mass of 13.6kDa (Molecular size on SDS-PAGE will appear at approximately 18-28kDa).
CD79A is expressed with a 8 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
CD79a Molecule, Membrane-Bound Immunoglobulin-Associated Protein, CD79A Antigen (Immunoglobulin-Associated Alpha), CD79a Molecule, Immunoglobulin-Associated Alpha, Surface IgM-Associated Protein, MB-1 Membrane Glycoprotein, Ig-Alpha, IGA, B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain, CD79a Antigen, MB-1, MB1.
Sf9, Insect cells.
LWMHKVPASL MVSLGEDAHF QCPHNSSNNA NVTWWRVLHG NYTWPPEFLG PGEDPNGTLI IQNVNKSHGG IYVCRVQEGN ESYQQSCGTY LRVRQPPPRP FLDMGEGTKN RLEHHHHHH.
Product Science Overview
CD79A is a transmembrane protein that forms a heterodimer with CD79B (Ig-beta). This heterodimer is non-covalently associated with membrane-bound immunoglobulins (IgM, IgD, IgG, etc.), forming the BCR complex . The BCR complex is responsible for recognizing specific antigens and initiating B-cell activation and signaling .
The cytoplasmic domain of CD79A contains immunoreceptor tyrosine-based activation motifs (ITAMs), which are critical for signal transduction. Upon antigen binding to the BCR, the ITAMs are phosphorylated, leading to the recruitment and activation of downstream signaling molecules such as Lyn and Syk kinases . This signaling cascade ultimately results in B-cell activation, proliferation, and differentiation .
CD79A expression begins at the pre-B cell stage and continues through to the plasma cell stage . It is found in the majority of B-cell lineage cells, including precursor B cells, mature B cells, and some plasma cells . CD79A is not present in myeloid or T-cell lineages .
The presence of CD79A is essential for the proper assembly and surface expression of the BCR complex. It also plays a role in the selection and maturation of B cells in the bone marrow . Mutations or deficiencies in CD79A can lead to immunodeficiencies, such as agammaglobulinemia, where B cells are unable to produce sufficient antibodies .
Recombinant CD79A is produced using various expression systems, such as HEK293 cells, to ensure proper folding and post-translational modifications . The recombinant protein is often tagged with a His-tag for purification purposes and is used in research to study B-cell signaling and function .
Recombinant CD79A is also utilized in the development of therapeutic antibodies and chimeric antigen receptor (CAR) T-cell therapies targeting B-cell malignancies and autoimmune diseases . These therapies aim to modulate B-cell activity by targeting the CD79A component of the BCR complex .
CD79A is a valuable marker for diagnosing B-cell lymphomas and leukemias . Its expression is often assessed in immunohistochemistry and flow cytometry to identify B-cell lineage cells in various hematological malignancies . Additionally, CD79A-targeted therapies are being explored for their potential to treat B-cell-related disorders .
